ADMA ADMA Biologics, Inc.

QT72

Latest market price

11.41

-0.34-2.89%

Overview Short InterestFilings

ADMAQT72ADMA Biologics, Inc.·NASDAQ

Overview Short InterestFilings

11.41-2.89%

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ZLAB-1.30%$22.07 PGEN+4.52%$6.94 MBX+2.44%$55.87 RXRX-4.95%$4.03 CLDX+0.70%$30.10 NAMS-3.37%$20.06 PHVS-0.15%$33.53 VRDN-0.52%$24.67

Snapshot

Index	—	P/E	16.30	EPS (ttm)	0.70	Insider Own	19.18%	Shs Outstand	223.99M	Perf Week	6.84%

Market Cap	2.56B	Forward P/E	12.10	EPS next Y	0.94	Insider Trans	0.07%	Shs Float	219.66M	Perf Month	14.90%

Enterprise Value	2.62B	PEG	0.75	EPS next Q	0.20			Short Float	8.89%	Perf Quarter	30.55%

Income	168.00M	P/S	5.00	EPS this Y	36.18%			Short Ratio	7.42	Perf Half Y	8.46%

Sales	511.00M	P/B	6.26	EPS next Y	18.41%	ROA	24.69%	Short Interest	19.53M	Perf YTD	-37.45%

Book/sh	1.82	P/C	18.79	EPS next 5Y	21.80%	ROE	39.59%	52W High	20.46 -44.23%	Perf Year	-26.53%

Cash/sh	0.61	P/FCF	21.84	EPS past 3/5Y	—	ROIC	27.55%	52W Low	7.21 58.25%	Perf 3Y	259.94%

Dividend Est.	—	EV/EBITDA	11.30	Sales past 3/5Y	49.06% 64.76%	Gross Margin	64.71%	Volatility	3.49% 3.53%	Perf 5Y	791.41%

Dividend TTM	—	EV/Sales	5.13	EPS Y/Y TTM	-18.60%	Oper. Margin	42.26%	ATR (14)	0.38	Perf 10Y	84.03%

Dividend Ex-Date	—	Quick Ratio	3.81	Sales Y/Y TTM	7.58%	Profit Margin	32.98%	RSI (14)	64.07	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	6.97	EPS Q/Q	6.67%	SMA20	6.15%	Beta	0.67	Target Price	18.67

Payout	0.00%	Debt/Eq	0.50	Sales Q/Q	1.64%	SMA50	14.11%	Rel Volume	0.91	Prev Close	11.75

Employees	644	LT Debt/Eq	0.49	Earnings	Nov 04	SMA200	4.12%	Avg Volume	2.70M	Price	11.41

IPO Date	Oct 17, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.04% -0.76%	Net Debt/EBITDA	0.29	Volume	2,460,408	Change	-2.89%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-15-26	Reiterated	Mizuho	Outperform	$24 → $17
Jun-10-26	Resumed	Raymond James	Outperform	$21
May-07-26	Reiterated	Canaccord Genuity	Buy	$21 → $18
Apr-20-26	Initiated	Canaccord	Buy	$21
Apr-13-26	Reiterated	Mizuho	Outperform	$14 → $24
Mar-26-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-14-24	Reiterated	HC Wainwright & Co.	Buy	$4.50 → $18
Jun-20-24	Reiterated	Mizuho	Buy	$6.00 → $14
Jan-03-23	Reiterated	HC Wainwright & Co.	Buy	$4.00 → $4.50
Nov-10-22	Reiterated	Mizuho	Buy	$6.00

Latest News· Times ET

Oct-30-26

Oct-30-2606:46PM

Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Notezacks.com

Oct-29-26

Oct-29-2610:31AM

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Betzacks.com

10:01AM

Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Knowzacks.com

Oct-28-26

Oct-28-2607:00AM

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026globenewswire.com

Oct-20-26

Oct-20-2606:51PM

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowingzacks.com

Oct-15-26

Oct-15-2610:22AM

How Investors May Respond To ADMA Biologics (ADMA) Peer‑Reviewed Validation Of IVIG Safety And PurityYahoo

07:00AM

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Processglobenewswire.com

Oct-12-26

Oct-12-2610:31AM

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?zacks.com

01:28AM

ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysisdefenseworld.net

Oct-09-26

Oct-09-2606:51AM

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Yahoo

Oct-08-26

Oct-08-2606:51PM

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investorszacks.com

10:00AM

ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Knowzacks.com

Oct-05-26

Oct-05-2604:28AM

ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Moderate Buy” from Analystsdefenseworld.net

Sep-29-26

Sep-29-2606:46PM

Here's Why Adma Biologics (ADMA) Fell More Than Broader Marketzacks.com

Sep-27-26

Sep-27-2609:06AM

ADMA Biologics (ADMA), Why Is It Back In The Spotlight?Yahoo

Company

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	511	510	426	258	—	—	—	—	—
Cost of Goods Sold Incl. D&A	181	217	207	169	—	—	—	—	—
Gross Profit	332	293	220	89	—	—	—	—	—
Selling, General and Administrative Excl. Other	101	92	74	59	—	—	—	—	—
Research and Development	12	5	2	3	—	—	—	—	—
Other Operating Expense	2	4	5	5	—	—	—	—	—
Operating Income	216	191	139	22	—	—	—	—	—
Interest Expense	9	7	14	25	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	8	-2	1	-25	—	—	—	—	—
Net Income Before Taxes	217	183	126	-28	—	—	—	—	—
Income Taxes	47	36	-72	0	—	—	—	—	—
Consolidated Net Income	168	147	198	-28	—	—	—	—	—
Net Income From Continuing Operations	168	147	198	-28	—	—	—	—	—
Net Income	168	147	198	-28	—	—	—	—	—
EPS (Recurring)	0.72	0.62	0.85	-0.13	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.72	0.62	0.85	-0.13	—	—	—	—	—
EPS (Diluted)	0.70	0.60	0.81	-0.13	—	—	—	—	—
EBITDA	232	198	148	5	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	16.30	30.40	21.17	—	—	—	—	—	—
Price To Sales Ratio	5.09	8.51	9.38	3.92	—	—	—	—	—
Gross Margin	64.97	57.45	51.64	34.50	—	—	—	—	—
Operating Margin	42.27	37.45	32.63	8.53	—	—	—	—	—
Net Margin	32.88	28.82	46.48	-10.85	—	—	—	—	—
Shares Outstanding	228	238	233	224	—	—	—	—	—
Market Capitalization	2,601	4,341	3,996	1,012	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grossman Jerrold B	Director	May 27 '26	Buy	7.91	6,400	50,624	520,284	May 28
Grossman Jerrold B	Director	May 12 '26	Buy	8.01	12,500	100,125	513,884	May 14
Grossman Jerrold B	Director	May 11 '26	Buy	8.01	12,500	100,125	501,384	May 12
Grossman Adam S	President and CEO	Mar 16 '26	Sale	15.16	21,000	318,360	2,112,777	Mar 17
Grossman Adam S	President and CEO	Mar 16 '26	Option Exercise	5.40	15,000	81,000	2,133,777	Mar 17
Guiheen Lawrence P.	Director	Mar 13 '26	Option Exercise	3.66	30,000	109,800	135,520	Mar 17
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Mar 09 '26	Option Exercise	3.20	10,096	32,330	476,696	Mar 10
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Mar 09 '26	Sale	15.63	10,096	157,800	466,600	Mar 10
ELMS STEVE	Director	Mar 06 '26	Buy	15.39	7,000	107,730	2,045,730	Mar 09
ELMS STEVE	Director	Mar 05 '26	Buy	15.67	7,000	109,690	2,038,730	Mar 09
Grossman Adam S	President and CEO	Feb 17 '26	Option Exercise	5.40	15,000	81,000	2,305,379	Feb 17
Grossman Adam S	President and CEO	Feb 17 '26	Sale	16.08	21,000	337,680	2,284,379	Feb 17
Grossman Adam S	President and CEO	Dec 15 '25	Sale	19.79	21,000	415,590	2,007,850	Dec 16
Grossman Adam S	President and CEO	Dec 15 '25	Option Exercise	5.40	15,000	81,000	2,028,850	Dec 16
Grossman Adam S	President and CEO	Nov 19 '25	Sale	16.00	21,000	336,000	2,013,850	Nov 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.